Polyrizon Ltd. announced the successful completion of patient enrollment and randomization for its multicenter U.S. clinical study evaluating NASARIX, an investigational intranasal hydrogel designed to protect against airborne allergens. The company randomized all 120 planned participants across five clinical research sites in the United States after screening 144 individuals. This milestone marks a key step in the development of the product candidate for treating allergic rhinitis using proprietary Capture and Contain technology. Polyrizon is a clinical-stage biotechnology company specializing in innovative intranasal hydrogels.
